Both Melittin (ME) and LL37 (L) are small linear helical peptides with multiply effects including antibacterial,anti-inflammation, anti-cancer and so on [1-3].However, they also have the undesirable property of cytotoxicity to red blood cells at a lower concentration (2 μM and 25-30 mM) which largely limit application widely in clinic[1-3].Recently,hybridizing of different antimicrobial peptides (AMPs) has been a common practice for obtaining novel hybrid AMPs with elevated antibacterial activity but minimized cytotoxicity[4, 5].The hybrid peptide ME (1-13)-L (17-30) (M-L)combining the hydrophobic N-terminal fragment of melittin (M) with the core antibacterial fragment of LL37 (L), was designed for the first time to explore its antibacterial activity and hemolytic activity against bacteria and sheep erythrocyte respectively.Results showed that M-L had an even more potent antibacterial activity against all indicator strains (especially gram-positive bacteria) than M and L, whereas did not exhibit hemolytic activity to sheep erythrocytes,implying M-L can be served as a potential therapeutic drug to substitute traditional antibiotics.However, the high expense of biosynthesis limited its further research, therefore fusion expression of M-L was carried out in Escherichia coli (E.coli)for overproducing the hybrid peptide so as to solve the problem.The DNA sequence encoding M-L with preferred codons was cloned into the pET-SUMO vector for protein expression in E.coli BL21 (DE3).After IPTG induction,approximately 165 mg soluble fusion protein SUMO-M-L was recovered per liter supernatant of the fermentation ultrasonic lysate using Ni-NTA sepharose column (92% purity).And 23 mg recombinant M-L was obtained per liter culture after cleavage of SUMO protease and purification of Ni-NTA sepharose column.In sum, this research not only supplied an effective approach for overproducing hybrid peptide M-L, but paved the way for its further exploration on pharmaceutical potential and medical importance.